TISIDB

Summary
Symbol	ARF1
Name	ADP-ribosylation factor 1
Aliases
Chromosomal Location	1q42.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Golgi apparatus Cytoplasm, perinuclear region Cell junction, synapse, synaptosome Cell junction, synapse, postsynaptic cell membrane, postsynaptic density Membrane Lipid-anchor
Domain	PF00025 ADP-ribosylation factor family
Function	GTP-binding protein that functions as an allosteric activator of the cholera toxin catalytic subunit, an ADP-ribosyltransferase. Involved in protein trafficking among different compartments. Modulates vesicle budding and uncoating within the Golgi complex. Deactivation induces the redistribution of the entire Golgi complex to the endoplasmic reticulum, suggesting a crucial role in protein trafficking. In its GTP-bound form, its triggers the association with coat proteins with the Golgi membrane. The hydrolysis of ARF1-bound GTP, which is mediated by ARFGAPs proteins, is required for dissociation of coat proteins from Golgi membranes and vesicles. The GTP-bound form interacts with PICK1 to limit PICK1-mediated inhibition of Arp2/3 complex activity; the function is linked to AMPA receptor (AMPAR) trafficking, regulation of synaptic plasicity of excitatory synapses and spine shrinkage during long-term depression (LTD).

> Gene Ontology [ TOP ]
Biological Process	GO:0002028 regulation of sodium ion transport GO:0002090 regulation of receptor internalization GO:0002478 antigen processing and presentation of exogenous peptide antigen GO:0002495 antigen processing and presentation of peptide antigen via MHC class II GO:0002504 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002697 regulation of immune effector process GO:0002831 regulation of response to biotic stimulus GO:0006644 phospholipid metabolic process GO:0006650 glycerophospholipid metabolic process GO:0006661 phosphatidylinositol biosynthetic process GO:0006814 sodium ion transport GO:0006875 cellular metal ion homeostasis GO:0006878 cellular copper ion homeostasis GO:0006887 exocytosis GO:0006888 ER to Golgi vesicle-mediated transport GO:0006892 post-Golgi vesicle-mediated transport GO:0006898 receptor-mediated endocytosis GO:0006900 membrane budding GO:0007015 actin filament organization GO:0007033 vacuole organization GO:0007034 vacuolar transport GO:0007040 lysosome organization GO:0007041 lysosomal transport GO:0008064 regulation of actin polymerization or depolymerization GO:0008154 actin polymerization or depolymerization GO:0008654 phospholipid biosynthetic process GO:0009306 protein secretion GO:0009615 response to virus GO:0010720 positive regulation of cell development GO:0010765 positive regulation of sodium ion transport GO:0010959 regulation of metal ion transport GO:0010975 regulation of neuron projection development GO:0010976 positive regulation of neuron projection development GO:0015672 monovalent inorganic cation transport GO:0016050 vesicle organization GO:0016197 endosomal transport GO:0016358 dendrite development GO:0017156 calcium ion regulated exocytosis GO:0017157 regulation of exocytosis GO:0017158 regulation of calcium ion-dependent exocytosis GO:0019216 regulation of lipid metabolic process GO:0019882 antigen processing and presentation GO:0019884 antigen processing and presentation of exogenous antigen GO:0019886 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0030041 actin filament polymerization GO:0030100 regulation of endocytosis GO:0030832 regulation of actin filament length GO:0030833 regulation of actin filament polymerization GO:0030838 positive regulation of actin filament polymerization GO:0031334 positive regulation of protein complex assembly GO:0031346 positive regulation of cell projection organization GO:0031623 receptor internalization GO:0032271 regulation of protein polymerization GO:0032273 positive regulation of protein polymerization GO:0032386 regulation of intracellular transport GO:0032388 positive regulation of intracellular transport GO:0032535 regulation of cellular component size GO:0032956 regulation of actin cytoskeleton organization GO:0032970 regulation of actin filament-based process GO:0034314 Arp2/3 complex-mediated actin nucleation GO:0034315 regulation of Arp2/3 complex-mediated actin nucleation GO:0034377 plasma lipoprotein particle assembly GO:0034379 very-low-density lipoprotein particle assembly GO:0034762 regulation of transmembrane transport GO:0034764 positive regulation of transmembrane transport GO:0034765 regulation of ion transmembrane transport GO:0034767 positive regulation of ion transmembrane transport GO:0035725 sodium ion transmembrane transport GO:0043112 receptor metabolic process GO:0043254 regulation of protein complex assembly GO:0043270 positive regulation of ion transport GO:0043900 regulation of multi-organism process GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism GO:0044089 positive regulation of cellular component biogenesis GO:0045010 actin nucleation GO:0045017 glycerolipid biosynthetic process GO:0045055 regulated exocytosis GO:0045324 late endosome to vacuole transport GO:0045666 positive regulation of neuron differentiation GO:0045807 positive regulation of endocytosis GO:0045921 positive regulation of exocytosis GO:0045956 positive regulation of calcium ion-dependent exocytosis GO:0046474 glycerophospholipid biosynthetic process GO:0046486 glycerolipid metabolic process GO:0046488 phosphatidylinositol metabolic process GO:0046916 cellular transition metal ion homeostasis GO:0048002 antigen processing and presentation of peptide antigen GO:0048167 regulation of synaptic plasticity GO:0048193 Golgi vesicle transport GO:0048259 regulation of receptor-mediated endocytosis GO:0048489 synaptic vesicle transport GO:0050688 regulation of defense response to virus GO:0050690 regulation of defense response to virus by virus GO:0050708 regulation of protein secretion GO:0050714 positive regulation of protein secretion GO:0050769 positive regulation of neurogenesis GO:0050773 regulation of dendrite development GO:0050792 regulation of viral process GO:0050804 modulation of synaptic transmission GO:0050805 negative regulation of synaptic transmission GO:0051047 positive regulation of secretion GO:0051125 regulation of actin nucleation GO:0051222 positive regulation of protein transport GO:0051258 protein polymerization GO:0051493 regulation of cytoskeleton organization GO:0051495 positive regulation of cytoskeleton organization GO:0051607 defense response to virus GO:0051640 organelle localization GO:0051648 vesicle localization GO:0051650 establishment of vesicle localization GO:0051656 establishment of organelle localization GO:0051962 positive regulation of nervous system development GO:0055070 copper ion homeostasis GO:0055076 transition metal ion homeostasis GO:0055108 Golgi to transport vesicle transport GO:0060292 long term synaptic depression GO:0060627 regulation of vesicle-mediated transport GO:0060628 regulation of ER to Golgi vesicle-mediated transport GO:0060996 dendritic spine development GO:0060998 regulation of dendritic spine development GO:0060999 positive regulation of dendritic spine development GO:0065005 protein-lipid complex assembly GO:0070142 synaptic vesicle budding GO:0071825 protein-lipid complex subunit organization GO:0071827 plasma lipoprotein particle organization GO:0080171 lytic vacuole organization GO:0090066 regulation of anatomical structure size GO:0097006 regulation of plasma lipoprotein particle levels GO:0097061 dendritic spine organization GO:0097212 lysosomal membrane organization GO:0097479 synaptic vesicle localization GO:0097480 establishment of synaptic vesicle localization GO:0098542 defense response to other organism GO:1900006 positive regulation of dendrite development GO:1902305 regulation of sodium ion transmembrane transport GO:1902307 positive regulation of sodium ion transmembrane transport GO:1902774 late endosome to lysosome transport GO:1902822 regulation of late endosome to lysosome transport GO:1902824 positive regulation of late endosome to lysosome transport GO:1902953 positive regulation of ER to Golgi vesicle-mediated transport GO:1903305 regulation of regulated secretory pathway GO:1903307 positive regulation of regulated secretory pathway GO:1903335 regulation of vacuolar transport GO:1903337 positive regulation of vacuolar transport GO:1903532 positive regulation of secretion by cell GO:1903725 regulation of phospholipid metabolic process GO:1904062 regulation of cation transmembrane transport GO:1904064 positive regulation of cation transmembrane transport GO:1904951 positive regulation of establishment of protein localization
Molecular Function	GO:0000287 magnesium ion binding GO:0003924 GTPase activity GO:0005057 receptor signaling protein activity GO:0005525 GTP binding GO:0008047 enzyme activator activity GO:0016004 phospholipase activator activity GO:0019001 guanyl nucleotide binding GO:0019003 GDP binding GO:0032561 guanyl ribonucleotide binding GO:0060229 lipase activator activity GO:1990583 phospholipase D activator activity
Cellular Component	GO:0005770 late endosome GO:0005777 peroxisome GO:0005778 peroxisomal membrane GO:0005798 Golgi-associated vesicle GO:0005802 trans-Golgi network GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0014069 postsynaptic density GO:0030016 myofibril GO:0030017 sarcomere GO:0030055 cell-substrate junction GO:0030135 coated vesicle GO:0030137 COPI-coated vesicle GO:0031252 cell leading edge GO:0031903 microbody membrane GO:0031984 organelle subcompartment GO:0042579 microbody GO:0043292 contractile fiber GO:0044438 microbody part GO:0044439 peroxisomal part GO:0044449 contractile fiber part GO:0045211 postsynaptic membrane GO:0060076 excitatory synapse GO:0097060 synaptic membrane GO:0098791 Golgi subcompartment GO:0098794 postsynapse GO:0099572 postsynaptic specialization

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04144 Endocytosis
Reactome	R-HSA-1280218: Adaptive Immune System R-HSA-446203: Asparagine N-linked glycosylation R-HSA-6811434: COPI-dependent Golgi-to-ER retrograde traffic R-HSA-6807878: COPI-mediated anterograde transport R-HSA-421837: Clathrin derived vesicle budding R-HSA-1643685: Disease R-HSA-199977: ER to Golgi Anterograde Transport R-HSA-432722: Golgi Associated Vesicle Biogenesis R-HSA-8856688: Golgi-to-ER retrograde transport R-HSA-162906: HIV Infection R-HSA-162909: Host Interactions of HIV factors R-HSA-168256: Immune System R-HSA-5663205: Infectious disease R-HSA-6811442: Intra-Golgi and retrograde Golgi-to-ER traffic R-HSA-6811438: Intra-Golgi traffic R-HSA-432720: Lysosome Vesicle Biogenesis R-HSA-2132295: MHC class II antigen presentation R-HSA-199991: Membrane Trafficking R-HSA-1430728: Metabolism R-HSA-556833: Metabolism of lipids and lipoproteins R-HSA-392499: Metabolism of proteins R-HSA-167590: Nef Mediated CD4 Down-regulation R-HSA-164938: Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters R-HSA-1483255: PI Metabolism R-HSA-1483257: Phospholipid metabolism R-HSA-597592: Post-translational protein modification R-HSA-1660514: Synthesis of PIPs at the Golgi membrane R-HSA-1660499: Synthesis of PIPs at the plasma membrane R-HSA-164952: The role of Nef in HIV-1 replication and disease pathogenesis R-HSA-948021: Transport to the Golgi and subsequent modification R-HSA-5653656: Vesicle-mediated transport R-HSA-199992: trans-Golgi Network Vesicle Budding

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04144 Endocytosis

Reactome

R-HSA-1280218: Adaptive Immune System
R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-6811434: COPI-dependent Golgi-to-ER retrograde traffic
R-HSA-6807878: COPI-mediated anterograde transport
R-HSA-421837: Clathrin derived vesicle budding
R-HSA-1643685: Disease
R-HSA-199977: ER to Golgi Anterograde Transport
R-HSA-432722: Golgi Associated Vesicle Biogenesis
R-HSA-8856688: Golgi-to-ER retrograde transport
R-HSA-162906: HIV Infection
R-HSA-162909: Host Interactions of HIV factors
R-HSA-168256: Immune System
R-HSA-5663205: Infectious disease
R-HSA-6811442: Intra-Golgi and retrograde Golgi-to-ER traffic
R-HSA-6811438: Intra-Golgi traffic
R-HSA-432720: Lysosome Vesicle Biogenesis
R-HSA-2132295: MHC class II antigen presentation
R-HSA-199991: Membrane Trafficking
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-392499: Metabolism of proteins
R-HSA-167590: Nef Mediated CD4 Down-regulation
R-HSA-164938: Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
R-HSA-1483255: PI Metabolism
R-HSA-1483257: Phospholipid metabolism
R-HSA-597592: Post-translational protein modification
R-HSA-1660514: Synthesis of PIPs at the Golgi membrane
R-HSA-1660499: Synthesis of PIPs at the plasma membrane
R-HSA-164952: The role of Nef in HIV-1 replication and disease pathogenesis
R-HSA-948021: Transport to the Golgi and subsequent modification
R-HSA-5653656: Vesicle-mediated transport
R-HSA-199992: trans-Golgi Network Vesicle Budding

Summary
Symbol	ARF1
Name	ADP-ribosylation factor 1
Aliases
Chromosomal Location	1q42.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between ARF1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between ARF1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
23804711	Chronic Lymphocytic Leukemia	Inhibit immunity	Transendothelial migration (TEM) of normal lymphocytes into lymph nodes requires the chemokine-induced activation of Rap1 and αLβ2 integrin. However, in most cases of CLL, Rap1 is refractory to chemokine stimulation, resulting in failed αLβ2 activation and TEM unless α4β1 is coexpressed. In this study, we show that the inability of CXCL12 to induce Rap1 GTP loading in CLL cells results from failure of Rap1-containing endosomes to translocate to the plasma membrane. Taken together, our findings indicate that chemokine unresponsiveness in CLL lymphocytes results from failure of Arf1/phospholipase D1-mediated translocation of Rap1 to the plasma membrane for GTP loading and may be a specific feature of anergy induced by DNA Ags.

Summary
Symbol	ARF1
Name	ADP-ribosylation factor 1
Aliases
Chromosomal Location	1q42.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of ARF1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	ARF1
Name	ADP-ribosylation factor 1
Aliases
Chromosomal Location	1q42.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of ARF1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.054	0.779
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.043	0.991
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.063	0.982
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.377	0.52
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.051	0.982
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.925	0.759
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.025	0.961
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.396	0.866
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.347	0.896
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.265	0.915
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.542	0.889
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.146	0.036

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of ARF1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	ARF1
Name	ADP-ribosylation factor 1
Aliases
Chromosomal Location	1q42.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ARF1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	ARF1
Name	ADP-ribosylation factor 1
Aliases
Chromosomal Location	1q42.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ARF1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ARF1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	ARF1
Name	ADP-ribosylation factor 1
Aliases
Chromosomal Location	1q42.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ARF1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	ARF1
Name	ADP-ribosylation factor 1
Aliases
Chromosomal Location	1q42.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of ARF1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	ARF1
Name	ADP-ribosylation factor 1
Aliases
Chromosomal Location	1q42.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between ARF1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	ARF1
Name	ADP-ribosylation factor 1
Aliases
Chromosomal Location	1q42.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting ARF1 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting ARF1.

ID	Name	Drug Type	Targets	#Targets
DB02774	1,3-Propandiol	Small Molecule	ARF1	1
DB04121	Guanosine-3'-Monophosphate-5'-Diphosphate	Small Molecule	ARF1	1
DB04137	Guanosine-5'-Triphosphate	Small Molecule	ADSSL1, ARF1, GLUD1, HRAS, PFKFB1, RAB5A, RAP2A, RHEB, RND3, UCKL1	10
DB04315	Guanosine-5'-Diphosphate	Small Molecule	ADSSL1, ARF1, ARF4, ARF6, ARL1, ARL3, ARL5A, ARL5B, CDC42, EEF1A1, ......	36
DB07348	Brefeldin A	Small Molecule	ARF1, CYTH2	2
DB08231	Myristic acid	Small Molecule	ABL1, ARF1, ARF6, ECI2, FKBP1A, GM2A, GUCA1A, HNF4A, INS, LY96, NC ......	20
DB09462	Glycerin	Small Molecule	ADH1B, ARF1, GSTP1, HPGDS, ISYNA1, ITPR1, NAGA, PAEP, PAPSS1, PLA2 ......	13

Browse ARF1